Investors & media
Financial data
Find the latest press releases, financial information, and performance updates.
Transforming rare disease care
We are a global specialty biopharmaceutical company expanding possibilities for people with rare diseases. With 50 years of experience in applying our scientific expertise and unique technologies to research, we continue to develop next-generation treatments and expand our global footprint to transform the lives of patients worldwide.
Newsroom
2026.06.17
JCR Pharmaceuticals announces that Acumen Pharmaceuticals has exercised its exclusive option to develop therapeutic candidates for Alzheimer’s Disease, enabled by J-Brain Cargo® Technology platform
2026.06.08
JCR Pharmaceuticals’ research presentations at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026 showcase data from its investigational treatments for lysosomal storage disorders
2026.05.28
JCR Pharmaceuticals to Present at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026
2026.05.26
JCR Pharmaceuticals receives “The Prize of the Minister of Education, Culture, Sports, Science, and Technology” at the 2026 National Commendation for Invention
2026.05.18
JCR Pharmaceuticals presents preclinical gene therapy data that demonstrate promising central nervous system uptake at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
Performance data and annual reports
JCR Pharmaceuticals (4552.T)
Tokyo Currency in JPY
475.00
+9.00
(+1.93%)
Last updated 06/18/2026 at TSE market close
Quarterly results
Annual reports
Driven by science and compassion, we tackle some of the most complex challenges in rare disease. Every solution we develop is grounded in insight into the genetic and biological foundations of the conditions we aim to treat.
Contact us
Investors & media